Year: 2016

Investigating the Role of Immunosuppressive Molecules in Ovarian Cancer

Powerful therapies that utilize a patient’s immune system (Immunotherapies) are being developed to treat ovarian cancer. Ovarian cancer tumors contain bad cells (tumor cells) and good cells (cells of the immune system)…

Read on

A “Trojan Horse” Mechanism That Mediates Resistance to Anti-VEGF Therapy

A factor that substantially contributes to the lethality of ovarian cancer is relapse which often occurs within 18 months after standard platinum-based chemotherapy…

Read on

The Effect of FoxM1 Inhibition on Ovarian Cancer Immunity and Sensitivity

Ovarian cancer is the fifth-most lethal cancer and deadliest of any gynecological cancer in the United States. The most common treatment for ovarian cancer is the removal of tumors, followed by platinum-based chemotherapy…

Read on

Co-Evolution of Epithelial Ovarian Cancer and Tumor Stroma

High Grade Serous Carcinoma (HGSC) is among the most lethal cancers affecting women in the U.S…

Read on

Microenvironment Mediated Stabilization of Hif-1 Alpha in Ovarian Cancer

Ovarian cancer (OvCa) patients are often diagnosed with advanced disease due to lack of early detection
methods. Once detected patients undertake surgery to remove tumor tissue and subsequently undergo
chemotherapy…

Read on

Novel Approaches to Immunotherapy

This project represents 4 novel approaches to ovarian cancer…

Read on

Crosstalk Between Glycolytic Pathway Inhibition and Increased Autophagy

Ovarian cancer (OvCa) patients respond to platinum and paclitaxel based therapies initially. However, almost 40-50% patients develop tumor recurrence within 3 years due to drug resistance. Therefore, newer drug targets and therapies are required…

Read on

Activation of Macrophages by Inhibiting CD47 Signaling in Ovarian Cancers

Activation of macrophages via inhibition of CD47 signaling is a novel therapeutic approach to cancers. Phagocytosis depends upon the balance of pro-phagocytic and anti-phagocytic inputs…

Read on

An Ovarian Cancer Biosensor for Rapid, Non-invasive Disease Detection

Ovarian cancer patient diagnosis and treatment is often limited by a lack of rapidly available information regarding their disease progression, response to treatment, and relapse…

Read on

Modeling Mullarian HGSC Using BRCA1 Patient Derived iPSCs

High grade serous cancer (HGSC) is the most common and malignant form of ovarian cancer with the highest incidence of mortality…

Read on

Ovarian Cancer Antigen Discovery by Single t-cell Analysis and pHLA Library

Because of a lack of early symptoms and effective screening tests, many ovarian cancer patients are diagnosed at advanced stages and more than half of them die of recurrent disease within 5 years of diagnosis…

Read on

Epigenetic Targeting of Cancer Stem-like Cells (CSCs) in Ovarian Cancer

Epithelial ovarian cancer (EOC) is the fifth most common cancer in women in the United States and the leading cause of death among gynecologic cancers…

Read on